Evidence map›Paper›PMID 40191726›Full record

ArticleOncology research2025

COPB2 promotes hepatocellular carcinoma progression through regulation of YAP1 nuclear translocation.

Biao Wu, Xianlin Guo, Zhishi Wu, Liang Chen, Suqing Zhang

Abstract read
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Biao WuDepartment of General Surgery, Changhai Hospital, Second (Navy) Military Medical University, Shanghai, 200433, China.
Xianlin GuoDepartment of General Surgery, Zhengzhou First People's Hospital, Zhengzhou, 450000, China.
Zhishi WuDepartment of General Surgery, Changhai Hospital, Second (Navy) Military Medical University, Shanghai, 200433, China.
Liang ChenDepartment of General Surgery, Changhai Hospital, Second (Navy) Military Medical University, Shanghai, 200433, China.
Suqing ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Tumor Hospital of Nantong University, Nantong, 226361, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Although Yes-associated protein 1 (YAP1) is an important oncogene in hepatocellular carcinoma (HCC) progression, its nuclear localization prevents it from being considered a potential therapeutic target. Recently, studies have reported that coatomer protein complex subunit beta 2 (COPB2) also plays a critical role in HCC development; however its mechanism of action is unclear. This study aimed to investigate the role of COPB2 and YAP1 in the progression of HCC and to elucidate the underlying mechanisms. Methods: COPB2 and YAP1 expression in HCC tissues were first analyzed by database searches and immunohistochemistry. Nomogram and artificial neural network models were established based on COPB2 and YAP1 expression. Cell proliferation was detected by cell counting kit-8 and clone formation assay, while cell migration and invasion were assessed using Transwell assays. Finally, the potential mechanisms underlying COPB2 regulation of YAP1 nuclear translocation were explored by immunofluorescence assay and Western blot. Results: COPB2 combined with YAP1 expression was associated with overall postoperative survival in HCC patients and was an independent prognostic factor. High expression of both COPB2 and YAP1 in patients may reduce the efficacy of postoperative transarterial chemoembolization therapy. Conclusions: Our findings suggest that COPB2/YAP1 affects the drug sensitivity of HCC cells to DDP and that targeting COPB2/YAP1 may be a promising strategy for the precision treatment of HCC.

Indexed as

Adaptor Proteins, Signal TransducingCarcinoma, HepatocellularLiver NeoplasmsTranscription FactorsCell Line, TumorCell MovementCell NucleusCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsCisplatin (DDP)Coatomer protein complex subunit beta 2 (COPB2)Hepatocellular carcinoma (HCC) prognosisYes-associated protein 1 (YAP1)

Identifiers

PMID40191726
PMCPMC11964868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.